The HemOnc Pulse Live at ASH: Tycel Phillips, MD, on the TRIANGLE Study, Frontline Therapy in MCL
By Chadi Nabhan, MD, MBA, FACP, Tycel Phillips, MD - Last Updated: December 16, 2022Tycel Phillips, MD, of the City of Hope, talks about the TRIANGLE study and frontline therapy in mantle cell lymphoma on The HemOnc Pulse, a podcast from Blood Cancers Today and the Society of Hematologic Oncology.
Post Tags:Lymphoma ASH 22
Advertisement
Related Posts
A phase I/II trial of LV20.19 showed a 100% ORR in patients with relapsed or refractory MCL.
Benefits of rituximab maintenance were observed despite the shift in first-line induction strategies over the years.
Brexucabtagene autoleucel in the standard-of-care setting for R/R MCL showed efficacy and toxicity “consistent” with ...
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Tycel Phillips, MD, discusses a study evaluating glofitamab in patients with relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726